COVID-19 and off label use of drugs: an ethical viewpoint

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

(2020) Ashley Barlow et al.   PHARMACOTHERAPY

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

(2020) J.M. Molina et al.   MEDECINE ET MALADIES INFECTIEUSES

Ethics codes and use of new and innovative drugs

(2018) Jan Borysowski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications

(2018) Carole A. Federico et al.   JAMA Internal Medicine

Association of Off-label Drug Use and Adverse Drug Events in an Adult Population

(2016) Tewodros Eguale et al.   JAMA Internal Medicine

Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs

(2015) Jonathan J. Darrow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Japanese Regulatory System for Approval of Off-Label Drug Use: Evaluation of Safety and Effectiveness in Literature-Based Applications

(2012) Rumiko Shimazawa et al.   CLINICAL THERAPEUTICS

Regulating Off-Label Drug Use — Rethinking the Role of the FDA

(2008) Randall S. Stafford   NEW ENGLAND JOURNAL OF MEDICINE